ArticleArchives of pharmacal research2025
Cartilage extracellular matrix regeneration with 10-gingerol via KEAP1-NRF2-ARE axis for osteoarthritis therapy.
Article in Archives of pharmacal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Oxeiptosis-Associated Molecular Subtyping and Immune Microenvironment Heterogeneity in Osteoarthritis.Biomedicines · 2026Article
- Wine-Processed Cornus officinalis Ameliorates Osteoarthritis via Modulating M1/M2 Macrophage Polarization.Journal of cellular and molecular medicine · 2026Article
- Nutritional Interventions in Osteoarthritis: Mechanisms, Clinical Evidence, and Translational Opportunities.Nutrients · 2026Review
- Eugenol preserves chondrocyte extracellular matrix homeostasis by modulating the ALK1/ALK5-associated TGF-β/Smad signaling axis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Osteoarthritis (OA) is characterized by oxidative stress, inflammation, and apoptosis, leading to an imbalance between cartilage extracellular matrix (ECM) synthesis and degradation. Gingerols can regulate multiple biological activities, indicating their therapeutic potential for OA. The present study investigated the feasibility, efficacy, and mechanism of gingerols for OA therapy. Regarding feasibility, gingerol exhibited antioxidant, anti-inflammatory, and antiapoptotic activities for OA therapy, while 10-G exhibited most potent effects among the three gingerols. Regarding efficacy, 10-G upregulated the expression of genes associated with ECM assembly and downregulated the expression of genes involved in ECM disassembly. Mechanistically, 10-G promoted NRF2 nuclear translocation; enhanced antioxidant gene expression; inhibited the phosphorylation of ERK, JNK, P38, RELA, and IKBA; and reduced the expression levels of TP53 and CDKN1A, thereby decreasing the production of inflammatory cytokines and apoptotic regulators. Furthermore, KEAP1 was identified as the direct target of 10-G, with NRF2 confirmed as the key regulatory target. This study demonstrates that 10-G mitigates oxidative stress, inflammation, and apoptosis through the KEAP1-NRF2-ARE axis and simultaneously restores ECM balance to promote cartilage regeneration, establishing its potential as a novel candidate for OA therapy.
Indexed as
Identifiers
41212495What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.